GSK Expands In Korea With Purchase Of Equity Stake In Dong-A Pharma
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline is paying 142.9 billion South Korean won ($128.7 million) to acquire a 9.9 percent stake in Dong-A Pharmaceutical, South Korea's leading Rx and OTC company. The strategic alliance should help GSK gain share in the rapidly growing Korean pharmaceutical market